First-in-human CAR T targets MUC1 transmembrane cleavage product.

被引：0
|
作者：
Bamdad, Cynthia [1 ]
Stewart, Andrew K. [1 ]
Huang, Pengyu [1 ]
Smagghe, Benoit J. [1 ]
Moe, Scott T. [1 ]
Swanson, Tyler E. [1 ]
Jeon, Thomas G. [1 ]
Page, Danica M. [1 ]
Grant, Trevor J. [1 ]
Specht, Jennifer M. [2 ]
机构：
[1] Minerva Biotechnol, Waltham, MA USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
57
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Regulation of human T cell response through MUC1 expression
    Agrawal, B
    Li, J
    Krantz, MJ
    Longenecker, BM
    Parker, J
    IMMUNOLOGY 2004: CYTOKINE NETWORK, REGULATORY CELLS, SIGNALING, AND APOPTOSIS, 2004, : 429 - 434
  • [32] MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma
    Mei, Zi
    Zhang, Kai
    Lam, Alfred King-Yin
    Huang, Junwen
    Qiu, Feng
    Qiao, Bin
    Zhang, Yi
    CANCER MEDICINE, 2020, 9 (02): : 640 - 652
  • [33] MUC1 Selectively Targets Human Pancreatic Cancer in Orthotopic Nude Mouse Models
    Park, Jeong Youp
    Hiroshima, Yukihiko
    Lee, Jin Young
    Maawy, Ali A.
    Hoffman, Robert M.
    Bouvet, Michael
    PLOS ONE, 2015, 10 (03):
  • [34] Immunohistochemical detection of the MUC1 gene product in human cancers grown in scid mice
    Schumacher, U
    Adam, E
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1998, 46 (01) : 127 - 134
  • [35] Phase I study of adoptive immunotherapy for advanced MUC1*positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
    Specht, Jennifer M.
    Maloney, David G.
    Yeung, Cecilia
    Wu, Vicky
    Bamdad, Cynthia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Phase I study of adoptive immunotherapy for advanced MUC1*positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)
    Specht, Jennifer Marie
    Maloney, David
    Yeung, Cecilia
    Wu, Qian
    Bamdad, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety
    Posey, Avery D., Jr.
    Clausen, Henrik
    June, Carl H.
    IMMUNITY, 2016, 45 (05) : 947 - 948
  • [38] Novel Benchmark Scaling Method for First-in-Human Dose of CAR-T Therapies
    Zhu, Xu
    Stein, Andrew
    Pearson, David
    Price, Andrew
    Sohoni, Akash
    Barton, Nathaniel
    Bradshaw, Laura
    Pinzon-Ortiz, Maria
    Bu, Dexiu
    Engels, Boris
    MOLECULAR THERAPY, 2022, 30 (04) : 524 - 524
  • [39] Old target, but new approach: Targeting cancer-associated MUC1 with ADC and Car-T
    Jung, Jin G.
    Kim, Min-Seok
    Jung, Hwa-Chul
    Choi, Hoil
    Moon, Kyung-Duk
    CANCER RESEARCH, 2020, 80 (16)
  • [40] Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function
    Yin, Li
    Ahmad, Rehan
    Kosugi, Michio
    Kufe, Turner
    Vasir, Baldev
    Avigan, David
    Kharbanda, Surender
    Kufe, Donald
    MOLECULAR PHARMACOLOGY, 2010, 78 (02) : 166 - 174
12345